Inhibitors of programmed death 1 (PD-1), programmed death ligand 1 (PD-L1), and cytotoxic T lymphocyte-associated antigen 4 (CTLA4) have demonstrated antitumor effects in malignant melanoma and non-small-cell lung cancer (Wang et al., 2022a). Here, CTLA4 is linked to melanoma.